The Cancer Epigenetics Society is very excited to announce the appointment of Dr. Lucy Godley to the Editorial Board of the Cancer Epigenetics journals series.
Dr. Godley is an expert of myeloid malignancies with a particular interest in DNA methylation and hydroxymethylation role in normal and neoplastic hematopoiesis. She also uses transgenic mouse models to study the role of truncated DNMT3B isoforms in cancer. In the clinical setting, Dr. Godley’s main area of expertise lays in bone marrow disorders, and she treats patients with leukemias, lymphomas, and multiple myeloma, as well as stem cell transplantation patients and those with benign hematologic conditions.
Dr. Godley received her MD from University of Northwestern University in Chicago and her PhD under Nobel Prize laureate Dr. Harold Varmus (co-discoverer of oncogenes) at University of California, San Francisco (UCSF). Her research was rewarded with the Howard Hughes Medical Institute (HHMI) Physician Postdoctoral Award. Other distinctions and honors include the Cancer and Leukemia Group B (CALGB) Foundation Clinical Research Award, the American Society of Clinical Oncology Young Investigator Award, the Cancer Research Foundation Young Investigator Award, the Schweppe Foundation Career Development Award, and the Kimmel Scholar Award. Dr. Godley is on the Committee on Cancer Biology at the Cancer Research Center of University of Chicago and is Professor of Hematology/Oncology at the Department of Medicine of University of Chicago. She was inducted into the American Society of Clinical Investigation in 2012.
In addition to the Cancer Epigenetics journal series, Dr. Godley is also on the Editorial Boards of Blood (ASH) and Clinical Cancer Research (AACR).
The Cancer Epigenetics Society is looking forward to working with Dr. Lucy Godley in advancing the field of DNA methylation and hydroxymethylation and understanding how these epigenetic events affect tumor genesis and progression (Cancer Epigenetics Society news, July 10, 2017).
